Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 161

The DOI matches its OpenAlex record.

Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall surviva

Kathy S. Albain, S. Nag, Germán Calderillo-Ruiz, J. P. Jordaan, Antonio Llombart‐Cussac, Anna Pluzanska, Marek Pawlicki, Allen S. Melemed, Joyce O’Shaughnessy, J. M. Reyes · 2004 · Journal of Clinical Oncology

Abstract

510 Background: GT had phase II safety and efficacy in MBC after anthracyclines, so it was compared to T in a phase III study of frontline therapy. Accrual goals were met in 4/02 and at initial planned interim analysis, GT significantly improved time to progression (TTP), progression-free survival (PFS), objective response rates (ORR) and quality of life, with an acceptable toxicity profile (PASCO 22:161, 2003). It was uncertain if this would translate into overall survival (OS) benefit, the primary endpoint of the trial. This report presents the first OS analysis. Methods: Patients (pts) with measurable MBC, prior (neo)adjuvant anthracyclines and KPS ≥70 were randomized to GT (G 1250 mg/m2 d1,8; T 175 mg/m2 d1) or T (175 mg/m2 d1) q21 days to progression. With median follow-up of 15.6 mos (all but 1 pt off study), the first OS analyses by Kaplan-Meier and Cox regression were conducted at approximately 75% (343) of the deaths needed (440) for the planned final OS report. (All p-values are 2-sided; confidence intervals, 95%.) Results: Characteristics of the 529 eligible pts (267 GT, 262 T) with visceral-dominant disease; toxicity; and the significant benefit from GT in ORR, TTP and PFS were previously reported (ref. above). 38% on GT stopped therapy due to progression vs 55% on T; therapy ended due to adverse events in 6.7%, GT vs 5.0%, T. The OS hazard ratio (HR) was 0.775 (.627, .959) in favor of GT, p=.018. Median OS for GT was 18.5 mos (16.5–21.2) vs T, 15.8 mos (14.4–17.4). One-year survival was 70.7% (65.1–76.3%) for GT and 60.9% (54.8–66.9%) for T (p=.019). The HR in favor of GT persisted in Cox regression after adjusting for baseline covariates: 0.740 (.598, .915), p=.006. Second-line therapy was nearly identical between arms, except for a 4-fold greater use of gemcitabine in the T arm. Conclusions: GT provides significant OS advantage over T when both are given on a q3 week cycle, a result to be confirmed in the final planned analysis in late 2004. The TTP benefit predicted OS improvement with longer follow-up. GT should be considered a frontline regimen in MBC. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eli Lilly Eli Lilly Eli Lilly

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

OpenAlex · 10.1200/jco.2004.22.14_suppl.510

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 161

Metadata

Authors
Albain, K. S., Nag, S., Calderillo-Ruiz, G., Jordaan, J. P., Llombart‐Cussac, A., Pluzanska, A., Pawlicki, M., Melemed, A. S., O’Shaughnessy, J., & Reyes, J. M.
Venue
Journal of Clinical Oncology
Publisher
Lippincott Williams & Wilkins
Published
2004-07-15
Volume
22
Issue
14_suppl
Pages
510-510
ISSN
0732-183X (ISSN-L)
OpenAlex
W2376751074
Cited by
161
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall surviva. https://app.cochat.ai/papers/10.1200/jco.2004.22.14_suppl.510
The paper
Albain, K. S., Nag, S., Calderillo-Ruiz, G., Jordaan, J. P., Llombart‐Cussac, A., Pluzanska, A., Pawlicki, M., Melemed, A. S., O’Shaughnessy, J., & Reyes, J. M. (2004). Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall surviva. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.22.14_suppl.510

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.